BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ocankitug readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ocankitug\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07418736-1336@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Ocankitug: Phase 2 readout est. (NCT07418736)
DESCRIPTION:Ocankitug\, phase 2\, Chronic Obstructive Pulmonary Disease.\nS
 tudy: A Phase II Study of CM326 in Subjects With Moderate to Severe Chroni
 c Obstructive Pulmonary Disease\nEstimated primary completion: 1 July 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/ocankitug#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07418736
URL:https://assetmemo.bio/drug/ocankitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07420257-1336@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Ocankitug: Phase 3 readout est. (NCT07420257)
DESCRIPTION:Ocankitug\, phase 3.\nStudy: A Randomized\, Double-blind\, Plac
 ebo-controlled Phase III Study to Evaluate the Efficacy and Safety of CM32
 6 in Participants With Chronic Rhinosinusitis With Nasal Polyposis\nEstima
 ted primary completion: 30 October 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/ocankitug#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07420257
URL:https://assetmemo.bio/drug/ocankitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07372287-1336@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ocankitug: Phase 3 readout est. (NCT07372287)
DESCRIPTION:Ocankitug\, phase 3\, Asthma.\nStudy: A Phase III Study of CM32
 6 in Subjects With Moderate to Severe Asthma\nEstimated primary completion
 : 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/o
 cankitug#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07372287
URL:https://assetmemo.bio/drug/ocankitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
